Latest news with #ThomasShrader
Globe and Mail
25-07-2025
- Business
- Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProMIS Neurosciences (PMN – Research Report) and Bruker (BRKR – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. ProMIS Neurosciences (PMN) In a report issued on July 21, Thomas Shrader from BTIG maintained a Buy rating on ProMIS Neurosciences, with a price target of $8.00. The company's shares closed last Thursday at $0.89, close to its 52-week low of $0.62. According to Shrader is a 1-star analyst with an average return of -0.2% and a 35.4% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Coya Therapeutics, Inc., and Arcturus Therapeutics. ;'> Currently, the analyst consensus on ProMIS Neurosciences is a Strong Buy with an average price target of $5.00, a 488.2% upside from current levels. In a report issued on July 14, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $4.00 price target. Bruker (BRKR) Leerink Partners analyst Puneet Souda maintained a Buy rating on Bruker on July 21 and set a price target of $65.00. The company's shares closed last Thursday at $40.27. According to Souda 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.3% and a 30.5% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. ;'> Currently, the analyst consensus on Bruker is a Moderate Buy with an average price target of $52.33, a 31.3% upside from current levels. In a report issued on July 19, TR | OpenAI – 4o also upgraded the stock to Buy with a $45.00 price target.
Yahoo
16-07-2025
- Business
- Yahoo
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target
Denali Therapeutics, Inc. (NASDAQ:DNLI) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 7, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics, Inc. (NASDAQ:DNLI) with a price target of $32.00. A doctor examining a patient's brain scan in a hospital setting displaying a neurological disorder. Basing the optimistic rating on the company's promising developments, the analyst reasoned that Denali Therapeutics, Inc. (NASDAQ:DNLI) has made notable developments in its enzyme replacement therapy, DNL-310, which the FDA has accepted for priority review for the treatment of Hunter Syndrome. He stated that therapy is significant for its ability to cross the blood-brain barrier, which may provide considerable advantages over the present treatments. With the FDA's acceptance showing strong regulatory support, the drug may attain an expedited path to the market. The firm also stated that Denali Therapeutics, Inc.'s (NASDAQ:DNLI) broader pipeline, which includes other Transport Vehicle-enabled therapies, also suggests the potential to address various neurological conditions. Denali Therapeutics, Inc. (NASDAQ:DNLI) develops and commercializes product candidates for the treatment of neurodegenerative diseases. Its product portfolio includes LRRK2, RIPK1, TREM2, and Tau. While we acknowledge the potential of DNLI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-07-2025
- Business
- Yahoo
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT
Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy rating on Novavax Inc. (NASDAQ:NVAX) with a $19 price target. A closeup of a vial of the biotechnology company's vaccines. BTIG analyst Thomas Shrader told investors following the company's announcement of the results of the initial cohort of its COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase 3 trial that the primary goal was to exhibit that the immunogenicity of both the COVID-19 and Influenza vaccines was within the protective range with 'interference' not being a strong factor. He stated that the first CIC data 'looks unremarkable – exactly what we hoped for,' adding that the 'most positive signs from today's data' were stronger immunogenicity for the Novavax flu vaccine for some antigens compared to the 'gold-standard' flu vaccine FLUZONE-HD. Novavax Inc. (NASDAQ:NVAX) is a biotechnology company that discovers, develops, and commercializes recombinant vaccines. While we acknowledge the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
19-05-2025
- Business
- Reuters
Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine
May 19 (Reuters) - Novavax (NVAX.O), opens new tab shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine from the U.S. health regulator, albeit with new conditions. The U.S. Food and Drug Administration approved the vaccine, Nuvaxovid, but limited its use to older adults and people over 12 years with conditions that put them at risk due to the illness. The conditions on the label are medically unusual but consistent with the chatter to date, said BTIG analyst Thomas Shrader. Analysts at Leerink Partners echoed the view. The approval is in line with expectations and "no more restrictive than we expected" from the Centers for Disease Control and Prevention's vaccine advisory committee, ACIP, they said. The vaccine's future was called into question after the FDA missed its April 1 deadline to approve the shot — a more traditional protein-based vaccine unlike its messenger RNA-based rivals. U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, also expressed concerns about the vaccine's efficacy in a CBS interview. Novavax missed out on the pandemic vaccine windfall — enjoyed by rivals Moderna (MRNA.O), opens new tab and Pfizer (PFE.N), opens new tab, which make messenger RNA-based vaccines — due to manufacturing issues and regulatory hurdles. The FDA's full approval of Nuvaxovid triggered a $175 million milestone payment to Novavax from Sanofi ( opens new tab, related to their licensing deal in 2024. Novavax expects to be ready for the commercial delivery of the shot in the U.S. this fall in partnership with Sanofi, pending strain recommendation. Novavax, along with its competitors, will need to seek additional approval to alter the strain of the virus its vaccine targets for the upcoming COVID-19 immunization season. This is set to be discussed at a meeting of FDA vaccine advisers later this week. Through last close, Novavax shares have fallen 16.3% so far this year.
Yahoo
19-05-2025
- Business
- Yahoo
Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine
(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine from the U.S. health regulator, albeit with new conditions. The U.S. Food and Drug Administration approved the vaccine, Nuvaxovid, but limited its use to older adults and people over 12 years with conditions that put them at risk due to the illness. The conditions on the label are medically unusual but consistent with the chatter to date, said BTIG analyst Thomas Shrader. Analysts at Leerink Partners echoed the view. The approval is in line with expectations and "no more restrictive than we expected" from the Centers for Disease Control and Prevention's vaccine advisory committee, ACIP, they said. The vaccine's future was called into question after the FDA missed its April 1 deadline to approve the shot — a more traditional protein-based vaccine unlike its messenger RNA-based rivals. U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, also expressed concerns about the vaccine's efficacy in a CBS interview. Novavax missed out on the pandemic vaccine windfall — enjoyed by rivals Moderna and Pfizer, which make messenger RNA-based vaccines — due to manufacturing issues and regulatory hurdles. The FDA's full approval of Nuvaxovid triggered a $175 million milestone payment to Novavax from Sanofi, related to their licensing deal in 2024. Novavax expects to be ready for the commercial delivery of the shot in the U.S. this fall in partnership with Sanofi, pending strain recommendation. Novavax, along with its competitors, will need to seek additional approval to alter the strain of the virus its vaccine targets for the upcoming COVID-19 immunization season. This is set to be discussed at a meeting of FDA vaccine advisers later this week. Through last close, Novavax shares have fallen 16.3% so far this year. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
